Pranlukast hydrate in the treatment of pediatric bronchial asthma

References

• National Institutes of Health. Global Initiative For Asthma: global strategy for asthma management and prevention. Available from: http://www.ginasthma.org. Accessed October 29, 2012.
   Google Scholar
• Weersink EJ, Postma DS, Aalbers R, de Monchy JG. Early and late asthmatic reaction after allergen challenge. Respir Med. 1994;88:103–114.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med. 2000;161:S68–S72.
   PubMed Web of Science ®Google Scholar
• Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med. 2000;161:S102–S106.
   PubMed Web of Science ®Google Scholar
• Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol. 1938;94:187–226.
   PubMedGoogle Scholar
• Kellaway CH, Trethewie ER. The liberation of a slow reacting smooth- muscle-stimulating substance in anaphylaxis. Q J Exp Physiol. 1940;30:121–145.
   Google Scholar
• Brocklehurst WE. The release of histamine and formation of a slow- reacting substance (SRS-A) during anaphylactic shock. J Physiol. 1960;151:416–435.
   PubMed Web of Science ®Google Scholar
• Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med. 2000;161:52–56.
   Web of Science ®Google Scholar
• Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001;61:285–315.
   PubMed Web of Science ®Google Scholar
• Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl AcadSci USA. 1979;76:4275–4279.
   PubMed Web of Science ®Google Scholar
• Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568–575.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5–1ipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645–655.
   PubMed Web of Science ®Google Scholar
• Lynch KR, O’Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789–793.
   PubMed Web of Science ®Google Scholar
• Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999;56:657–663.
   PubMed Web of Science ®Google Scholar
• Nothacker H-P, Wang Z, Zhu Y, et al. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000;58:1601–1608.
   PubMed Web of Science ®Google Scholar
• Heise CE, O’Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531–30536.
   PubMed Web of Science ®Google Scholar
• Leff AR. Discovery of leukotrienes and development of antileukotriene agents. Ann Allergy Asthma Immunol. 2001;86 Suppl:4–8.
   Web of Science ®Google Scholar
• O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997;111 Suppl:27S-34S.
   Google Scholar
• Dahlen B, Dahlen SE. Leukotrienes as mediators of airway obstruction and inflammation in asthma. Clin Exp Allergy. 1995;25 Suppl 2:50–54.
   Google Scholar
• Dahlen SE. Leukotriene receptors. Clin Rev Allergy Immunol. 1999;17:179–191.
   Web of Science ®Google Scholar
• Dahlen SE. Pharmacological characterization of leukotriene receptors. Am J Respir Crit Care Med. 2000;161:S41–S45.
   Web of Science ®Google Scholar
• Labat C, Ortiz JL, Norel X, et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther. 1992;263:800–805.
   PubMed Web of Science ®Google Scholar
• Walch L, Norel X, Back M, et al. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol. 2002;137:1339–1345.
   PubMed Web of Science ®Google Scholar
• Yonetomi Y, Fujita M, Nakagawa N, et al. Preclinical pharmacology of pranlukast. Clin Exp Allergy Rev. 2001;1:210–217.
   Google Scholar
• Mikawa H, Baba M. Efficacy and safety of a leukotriene antagonist; ONO-1078 dry syrup, on pediatric bronchial asthma – dose finding study in a multi-center, open trial. Rinsho Iyaku. 1997;13(2):395–421. Japanese.
   Google Scholar
• Mikawa H, Baba M, Nakashima M. Clinical usefulness of a leukotriene antagonist; pranlukast dry syrup on pediatric bronchial asthma in multi-center comparative double-blind clinical study with oxatomide dry syrup. Rinsho Iyaku. 1997;13:423–456. Japanese.
   Google Scholar
• Iikura Y, Saito H, Sakaguchi N, et al. Efficacy and safety of long-term use of a leukotriene C4, D4 and E4 antagonist, ONO-1078 dry syrup, in pediatric bronchial asthma. Rinsho Iyaku. 1997;13:1015–1039. Japanese.
   Google Scholar
• Toyoshima K, Kameda M, Mikawa H, et al. Efficacy and safety of a long-term (12 weeks) use of a leukotrieneC4, D4 and E4 antagonist, ONO-1078 dry syrup, in asthmatic children. Rinsho Iyaku. 1997;13:1041–1071. Japanese.
   Google Scholar
• Hata D, Shiota M, Tamura Y, et al. The effectiveness of long-term treatment with pranlukast in pediatric patients with mild to moderate asthma. Arerugi. 2002;51:400–410. Japanese.
   PubMedGoogle Scholar
• Iwata T, Kurihara K, Odajima Y, et al. Safety and effectiveness of Onon dry syrup 10% (pranlukast hydrate) in children aged less than 1 year with bronchial asthma – prospective study. Jpn J Pediatr Allergy Clin Immunol. 2009;23:629–642. Japanese.
   Google Scholar
• Nishimuta T, Kondo N, Hamasaki Y, et al. Japanese guideline for childhood asthma. Allergol Int. 2011;60:147–169.
   PubMedGoogle Scholar
• Iwata T, Kurihara K, Odajima Y, et al. Safety and effectiveness of Onon dry syrup (pranlukast hydrate) in children aged less than 1 year with bronchial asthma – follow-up study of long-term use. Jpn J Pediatr Allergy Clin Immunol. 2010;24:693–704. Japanese.
   Google Scholar
• Inoue R, Teramoto T, Nakade S, et al. Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma. Allergol Int. 2003;52:213–218.
   Google Scholar
• Kondo N, Teramoto T, Inoue R, et al. Evaluation before and after pranlukast administration with the QOL questionnaire (revised version 2001) for pediatric patients with bronchial asthma and their parents or caregivers. Arerugi. 2002;51:421–429. Japanese.
   Google Scholar
• Nishima S, Furusho K, Morikawa A, et al. Pranlukast inhibits exercise- induced bronchospasm in asthmatic children: a randomized, multicenter, double-blind, placebo-controlled two-period crossover trial. Pediatr Asthma Allergy Immunol. 2005;18:5–11.
   Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am JRespir Crit Care Med. 2008;178:667–672.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen BG, DeJong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–724.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Yamada Y, Abe T, Linden A, Arisaka O. Association of epithelial damage and signs of neutrophil mobilization in the airways during acute exacerbations of paediatric asthma. Clin Exp Immunol. 2006;144:212–216.
   PubMed Web of Science ®Google Scholar
• Laprise C, Laviolette M, Boutet M, Boulet LP. Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling. Eur Respir J. 1999;14:63–73.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Fukuda H, Abe T, et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. AllergolInt. 2012;61:405–410.
   Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–556.
   PubMed Web of Science ®Google Scholar
• Yamakawa Y, Ohtsuka Y, Ohtani K, et al. Effects of leukotriene receptor antagonists on peripheral eosinophil counts and serum IgE levels in children with food allergy. Drugs R D. 2010;10:147–154.
   Google Scholar
• Hashiguchi K, Tang H, Fujita T, et al. Validation study of the OHIO chamber in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2009;149:141–149.
   PubMed Web of Science ®Google Scholar
• Hashiguchi K, Tang H, Fujita T, et al. Preliminary study on Japanese cedar pollinosis in a artificial exposure chamber (OHIO chamber). Allergol Int. 2007;56:125–130.
   PubMedGoogle Scholar
• Wakabayashi K, Hashiguchi K, Kanzaki S, et al. Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. Allergy Asthma Proc. 2012;33:1–8.
   Web of Science ®Google Scholar